Xencor, Inc. is a pioneering clinical-stage biopharmaceutical company headquartered in Monrovia, California, dedicated to developing advanced cytokine and monoclonal antibody therapies that target critical unmet needs in oncology and autoimmune diseases. Leveraging its proprietary XmAb technology platform, Xencor enhances both the efficacy and safety profiles of its drug candidates, thereby positioning itself strategically within the dynamic biopharmaceutical landscape. With a robust and diverse pipeline poised for clinical advancement, the company is well-positioned to deliver innovative treatments that could significantly improve patient outcomes, making it an attractive investment opportunity for institutional investors in the biopharmaceutical sector. Show more

Location: 465 NORTH HALSTEAD STREET, PASADENA, CA, UNITED STATES, 91107, Pasadena, CA, 91107, USA | Website: https://www.xencor.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

863.4M

52 Wk Range

$6.92 - $18.69

Previous Close

$12.09

Open

$12.00

Volume

584,809

Day Range

$11.85 - $12.42

Enterprise Value

482.3M

Cash

28.29M

Avg Qtr Burn

-30.82M

Insider Ownership

1.25%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Xaluritamig (STEAP1-CD3 Bispecific) Details Metastatic Castration-Resistant Prostate Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obexelimab (CD19) Details IgG4-Related Disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details Renal cell carcinoma, Cancer, Prostate cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Plamotamab (CD20xCD3) Details Autoimmune disease, Rheumatoid arthritis	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb808 + pembrolizumab Details Solid tumor/s, Prostate cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Plamotamab (CD20xCD3) Details Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, B-cell malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb541 (CLDN6 x CD3) Details Ovarian cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb819 (ENPP3 x CD3) Details Clear cell renal cell carcinoma (ccRCC)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb942 Details Inflammatory bowel disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ASP2138 (Claudin18.2-CD3 Bispecific) Details Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb662 (IL12-Fc) Details Cancer, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb657 Details Autoimmune disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb412 (TL1A/IL23p19 Bispecific) Details Inflammatory Bowel Disease	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb564 (IL-2-Fc) Details Autoimmune disease, Psoriasis, Atopic dermatitis	Phase 1a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tidutamab (SSTR2xCD3) Details Cancer, Neuroendocrine tumor, Gastrointestinal stromal tumors	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details Cancer, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vibecotamab (CD123xCD3) Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.